Here are five things you must know for Thursday, Nov. 19:
Stock futures declined Thursday as optimism over a possible coronavirus vaccine was overshadowed by worries that tighter restrictions to control the spread of the virus will lead to further economic damage.
Contracts linked to the Dow Jones Industrial Average fell 37 points, S&P 500 futures declined 2 points and Nasdaq futures were down 26 points.
Stocks ended lower Wednesday as the gains that came from Pfizer’s (PFE) – Get Report more promising vaccine data were erased after New York City moved to close public schools again as virus transmission in the nation’s largest school system spiked.
The Dow fell 345 points, or 1.16%, to close at 29,438, the S&P 500 finished down 1.16% and the Nasdaq declined 0.8%.
Deaths in the U.S. from Covid-19, the disease caused by the coronavirus, have surpassed 250,000, the most in the world, according to Johns Hopkins University. Experts have predicted the country could soon be reporting 2,000 deaths a day or more, matching or exceeding the spring peak, and that 100,000 to 200,000 more Americans could die in the coming months, The New York Times said in a report.
That’s why word from Pfizer and its German partner BioNTech (BNTX) – Get Report that their coronavirus vaccine candidate reached a 95% efficacy rate was welcome by Wall Street. The companies said they will apply for emergency use authorization from the Food and Drug Administration in the coming days.
But while the world waits for a vaccine to be approved – and then distributed – concerns remain over what fallout growing restrictions on businesses will have on the U.S. and global economies.
Asian shares finished Thursday’s session mostly to the downside while European stocks traded lower.
For more on Asian markets read:
U.S.-listed shares of AstraZeneca (AZN) – Get Report were rising in premarket trading Thursday after it was confirmed a coronavirus vaccine the company is developing with the University of Oxford produced a strong immune response “across all age groups,” particularly older people.
“It is essential that a Covid-19 vaccine can be effective across a broad age range, particularly in older individuals where they are disproportionately at risk of severe Covid-19 disease,” said Mene Pangalos, AstraZeneca’s executive vice president of biopharmaceuticals research and development.
The results of the study were published Thursday in The Lancet medical journal.
American depositary receipts of AstraZeneca rose 0.78% to $54.41 a share.
The results from Oxford’s phase 2 study showed the vaccine was better tolerated in older people and produced a similar immune response in old and young adults.
Oxford said it expects final-stage efficacy results to be released in the coming weeks.
Nvidia (NVDA) – Get Report, a big winner during the coronavirus pandemic, posted a 57% jump in third-quarter revenue as sales of its chips used for gaming and home computing powered the gains.
Revenue in the period of $4.73 billion topped analysts’ estimates of $4.41 billion. Earnings in the quarter were $2.91 a share vs. expectations of $2.57.
“Nvidia is firing on all cylinders, achieving record revenues in gaming, data center and overall,” said Jensen Huang, the company’s founder and CEO. “The new Nvidia GeForce RTX GPU provides our largest-ever generational leap and demand is overwhelming. Nvidia RTX has made ray tracing the new standard in gaming.”
The stock declined 1.89% to $527 in premarket trading. Nvidia shares have risen nearly 130% so far in 2020.
The company’s gaming chip segment, its largest business, posted revenue of $2.27 billion, up 37% from a year earlier.
Nvidia said it expects fourth-quarter revenue of $4.8 billion, plus or minus 2%, putting it ahead of analysts’ expectations of $4.42 billion.
“All in, this was another exceptional quarter from Nvidia as the company topped expectations on practically every single line item,” said Jim Cramer and the Action Alerts PLUS team, which holds Nvidia in its portfolio.
The economic calendar in the U.S. Thursday includes weekly Jobless Claims at 8:30 a.m. ET, the Philadelphia Fed Manufacturing Index for November at 8:30 a.m. and Existing Home Sales for October at 10 a.m.
Macy’s (M) – Get Report posted a third-quarter adjusted loss of 19 cents a share, narrower than expectations that called for a loss of 83 cents.
The retailer posted sales in the period of $3.99 billion vs. estimates of $3.91 billion. Same-store sales declined 21% but the drop was narrower than forecast. The stock fell 4% in premarket trading.
Earnings reports are also expected Thursday from Ross Stores (ROST) – Get Report, BJ’s Wholesale Club (BJ) – Get Report, Intuit (INTU) – Get Report and Workday (WDAY) – Get Report.
Starbucks (SBUX) – Get Report will be raising employee pay by at least 10%.
The giant coffee chain disclosed the move in a memo distributed to employees earlier in November, according to multiple reports.
Starbucks will raise wages by at least 10% for baristas, shift supervisors and cafe attendants that were hired on or before Sept. 14. The increase will go into effect in mid-December.
Starting pay rates will rise 5% “so our store managers can continue to attract and retain new talent,” Starbucks Executive Vice President Rossann Williams said in a memo that was seen by Bloomberg.
Restaurants have had difficulty keeping staff because potential employees are afraid of contracting the coronavirus, Bloomberg noted. Even though unemployment remains high during the pandemic, the increased exposure that service sector workers face has made harder for companies to attract and maintain staff.
Reviewed By This Is Article About Nvidia, AstraZeneca, Starbucks, Macy’s: 5 Things You Must Know was posted on have 4 stars rating.